Akari Therapeutics (AKTX) AI Stock Analysis

• Market Cap: $9.19M
• Dividend Yield: N/A
• Average Volume (3M): 1.63M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 45,783,504
• 10 Day Avg. Volume: 2,851,768
• 30 Day Avg. Volume: 1,628,756
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 3.87
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -35.60K
• Enterprise Value/Ebitda: -2.16
• 1Y Price Target: $3.33
• Price Target Upside: 1090.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.25 ▼(-10.36% Downside)

The score is pressured primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events are mixed—financing helps liquidity, but the Nasdaq delisting risk is a significant overhang—while valuation inputs are unavailable, limiting conviction from that component.

Positive Factors

Leadership Change

The appointment of a new CEO with a strong industry background is expected to bring strategic insights and strengthen Akari's market position, potentially impacting the company's future direction positively.

Debt Management

Prudent capital management with low debt levels provides financial flexibility and reduces risk, allowing the company to focus on product development without heavy debt burdens.

Strategic Partnerships

Strategic partnerships with larger pharmaceutical companies can provide essential resources and market access, supporting Akari's drug development and commercialization efforts.

Negative Factors

Financial Instability

The lack of revenue and consistent losses highlight financial instability, posing a significant risk to sustainability and requiring successful product development for future viability.

Cash Flow Dependency

Negative cash flow and reliance on external financing indicate a high risk of cash shortages, which could constrain operations if financing becomes limited.

Operational Losses

Persistent operational losses without revenue generation challenge financial sustainability, necessitating successful commercialization to transition to profitability.

Akari Therapeutics Business Overview & Revenue Model

Company Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

How the Company Makes Money

Akari Therapeutics primarily makes money through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships, licensing agreements, and potential sales of its therapeutic products upon receiving regulatory approval. Key revenue streams include milestone payments and royalties from strategic collaborations with larger pharmaceutical companies that have the resources to bring Akari's products to market. Additionally, Akari may receive research and development funding from grants or governmental and non-governmental organizations, supporting its ongoing drug development efforts.

Akari Therapeutics Financial Statement Overview

Summary

Akari Therapeutics is in an early-stage biotechnology phase with no revenue generation and consistent losses, leading to negative cash flow and reliance on external financing. While the company's debt levels are low, the financial instability is evident from the fluctuating equity and persistent cash burn. Sustained financial health will depend on successful product development and commercialization to transition from a loss-making to a revenue-generating entity.

Income Statement

Akari Therapeutics has not generated any revenue over the past years, which is typical for early-stage biotechnology companies but poses a significant risk in terms of financial sustainability. The company reports consistent negative EBIT and net income, indicating ongoing operational losses without any top-line growth. The inability to generate revenue while incurring significant expenses results in a challenging financial position.

Balance Sheet

Despite having no revenue, Akari Therapeutics maintains a relatively low level of debt compared to its equity, demonstrating prudent capital management. However, stockholders' equity has fluctuated, with a substantial deficit in 2023, which indicates financial instability. The equity ratio remains modest, reflecting a need for improved financial performance to stabilize the balance sheet.

Cash Flow

The company has experienced negative operating cash flow consistently, signaling cash burn due to lack of revenue. Although financing cash flow has supported operations through equity raises or debt, the free cash flow remains negative, highlighting the dependency on external financing to sustain operations. This situation underscores the high risk of cash flow shortages if financing becomes constrained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.00K	0.00	0.00	0.00	0.00	0.00
EBITDA	-16.46M	-19.53M	-16.80M	-23.08M	-17.21M	-17.97M
Net Income	-15.73M	-19.79M	-10.01M	-17.75M	-17.42M	-17.08M
Balance Sheet
Total Assets	45.38M	50.56M	4.36M	13.83M	11.65M	14.60M
Cash, Cash Equivalents and Short-Term Investments	2.48M	2.60M	3.85M	13.25M	9.36M	14.06M
Total Debt	2.12M	3.26M	0.00	0.00	0.00	0.00
Total Liabilities	22.69M	28.33M	4.58M	12.04M	6.09M	5.22M
Stockholders Equity	22.69M	22.23M	-229.00K	1.79M	5.55M	9.38M
Cash Flow
Free Cash Flow	-9.63M	-12.55M	-16.43M	-21.50M	-18.85M	-16.95M
Operating Cash Flow	-9.63M	-12.55M	-16.43M	-21.50M	-18.85M	-16.95M
Investing Cash Flow	382.00K	382.00K	0.00	0.00	0.00	0.00
Financing Cash Flow	9.54M	10.99M	7.02M	25.29M	14.29M	25.07M

Akari Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AKTX, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.42, and below the 200-day MA of 0.92, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 37.97 is Neutral, neither overbought nor oversold. The STOCH value of 46.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AKTX.

Akari Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	50 Neutral	$175.19M	-1.21	-21.16%	―	-92.42%	62.37%
PASG	49 Neutral	$61.94M	-1.24	-87.18%	―	―	38.42%
MBRX	45 Neutral	$12.26M	-0.07	―	―	―	79.31%
NNVC	43 Neutral	$24.16M	-2.22	-94.03%	―	―	32.92%
AKTX	42 Neutral	$9.19M	―	-196.60%	―	―	―

Akari Therapeutics Corporate Events

Akari Therapeutics Announces $5M Financing Agreement

Akari Therapeutics announced on December 16, 2025, that it entered into agreements to raise approximately $5 million through a registered direct offering and concurrent private placements of American Depositary Shares (ADSs) and warrants, with significant participation from company executives and institutional investors. The financing will support research and development, working capital, and corporate activities, while reducing its liabilities through a $2.50 million debt exchange into warrants, enhancing both financial flexibility and capital structure. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering.

The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.

Akari Therapeutics Approves Key Resolutions at Meeting

On December 15, 2025, Akari Therapeutics held a Special General Meeting where shareholders approved several resolutions, including the exercisability of certain warrants and the issuance of ordinary shares related to a previous securities offering. The meeting also resulted in the approval of a share subdivision, authorization for directors to allot shares, and a share buyback contract, which are expected to impact the company’s financial structure and shareholder value positively.

The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.

Akari Therapeutics Prepares Investor Presentation for Conferences

On December 8, 2025, Akari Therapeutics, Plc prepared an investor presentation for upcoming conferences and meetings. The presentation, which is part of a Current Report on Form 8-K, is intended to inform stakeholders but is not filed under the Securities Exchange Act of 1934, indicating it is for informational purposes only and not subject to certain legal liabilities.

The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.

Akari Therapeutics Faces Nasdaq Delisting Notice

On November 24, 2025, Akari Therapeutics received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has until May 25, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. If compliance is not regained, Akari may qualify for an additional 180-day compliance period or face potential delisting, with options to appeal. The company is considering strategies to address the issue, including a possible ratio change of its American Depositary Shares.

The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.

Akari Therapeutics Appoints Kameel Farag as Interim CFO

On October 22, 2025, Akari Therapeutics appointed Kameel Farag as interim Chief Financial Officer, succeeding Torsten Hombeck. Farag, with a robust background in biotechnology and finance, has been involved in significant growth and financial operations at companies like Aspen Neuroscience and Amgen Inc. His appointment is accompanied by a Consulting Agreement that outlines his compensation and potential incentives related to capital raises, highlighting the company’s strategic focus on financial management and growth.

The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.

Akari Therapeutics Announces $2.5 Million Direct Offering

On October 14, 2025, Akari Therapeutics entered into a securities purchase agreement with institutional investors for a direct offering of 3,125,000 American Depositary Shares (ADSs) and accompanying warrants, expected to raise approximately $2.5 million. The proceeds will be used for working capital, corporate purposes, and research and development, specifically to enhance data on a novel ADC payload for cancer treatment, with the offering expected to close around October 16, 2025.

The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.

Akari Therapeutics Announces $2.5 Million Direct Offering

On October 15, 2025, Akari Therapeutics announced a $2.5 million registered direct offering. This financial move is expected to impact the company’s operations by providing additional capital, potentially enhancing its market positioning and offering implications for stakeholders.

The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.